All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
Bookmark this article
During the 17th ICML, the Lymphoma Hub spoke with Georg Lenz, Münster University Hospital, Münster, DE. We asked for a summary of Pola-R-CHP (polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisolone) vs R-CHOEP (cyclophosphamide, doxorubicin, prednisone, rituximab, vincristine and etoposide) treatment in young patients with high-risk diffuse large B-cell lymphoma (DLBCL). Lenz highlights the efficacy and safety data of each treatment for this population of patients.
Pola-R-CHP vs R-CHOEP in young patients with high-risk DLBCL
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Phase II study of lenalidomide and R-CHOP in patients with diffuse large B-cell lymphoma
Diffuse large B-cell lymphoma (DLBCL) is recognized to be a molecularly heterogenous malignancy. Of the three main subtypes, the activated B-cell-like (ABC)...
Polatuzumab vedotin for naive DLBCL: Results from a phase 1b-2 trial
The primary objective of this ongoing, multicenter, open-label, non-randomized, phase Ib-II trial was treatment safety and tolerability, as well as the determination of the maximum...
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox